Kornimate/medical-research-clean huggingface dataset:
ultrasound-induced adipose tissue cavitation and training in obesity

Conditions: Obesity

Summary: the addition of ultrasound-induced adipose tissue cavitation (uatc) at the level of the abdominal subcutaneous adipose tissue may seem relevant as an additive treatment option to exercise intervention in individuals with obesity. however, whether individuals with obesity who participate in an exercise intervention and additionally undergo uatc, are more likely to develop a metabolically healthy phenotype, as opposed to subjects with obesity undergoing exercise training or uatc only, remains to be studied. therefore, the first aim of this study is to examine the impact of combined uatc during exercise intervention on abdominal subcutaneous and whole-body adipose tissue mass, quality of life and cardiometabolic risk in individuals with abdominal obesity.


Eligibility criteria:
inclusion criteria: * male/female (1:1), * age 18-65 y, * abdominal obesity (waist circumference \>102cm or \>88cm) - exclusion criteria: * involvement in dietary or exercise intervention in the last year, * intake of any medication, * clinically diagnosed diseases (cardiovascular disease, hypertension, venous thromboses blood diseases, presence of a pacemaker/defibrillator, brain or nervous system diseases, kidney, thyroid or liver disease, chronic inflammatory diseases, cancer, osteoporosis and epilepsy). * persons with a pregnancy, * a recent bone injury or the presence of a metal prothese
surgical treatment of hydatid liver disease

Conditions: Hydatid Cyst, Hepatic

Summary: the goal of this observational study is to show that cyst extraction with pericyst reduction and omentopexy is a suitable treatment for liver hydatid disease caused by e.granulossus with a low rate of complication and recurrence.


Eligibility criteria:
inclusion criteria: * hydatid liver disease exclusion criteria: * hydatid disease present outside the liver
natural history study of patients with leber congenital amaurosis associated with mutations in rpe65

Conditions: Leber Congenital Amaurosis

Summary: mgt005 is a natural history study to collect longitudinal prospective data from patients with leber congenital amaurosis associated with defects in rpe65.

leber congenital amaurosis (lca) is a diagnosis for a group of severe, autosomal recessively inherited rod - cone dystrophies that typically result in complete visual loss in the third or fourth decade of life. one form, lca2, is caused by a mutation in the gene encoding rpe56, an rpe-specific 65-kda isomerase. non-functional rpe65 results in photoreceptor cells that are unable to respond to light resulting in these patients being visually impaired. in preparation for human clinical trials, a detailed prospective phenotypic study will be undertaken to investigate the natural history of rpe65-lca. such a study will help identify suitable patients for therapeutic intervention. furthermore through greater phenotyping an optimal window for intervention and specific parameters to help quantify effect and identify clinical end points may have been ascertained .

Eligibility criteria:
inclusion criteria: * patients with rpe65 associated retinal dystrophy * minimum subject age of 3 years * able to give consent/parent or guardian able to give consent exclusion criteria: * patients unable or unwilling to undertake consent or clinical testing * have received a gene therapy treatment in both eyes
genetic pathways leading to fatty liver and atherogenic dyslipidemia

Conditions: Non-alcoholic Fatty Liver; Atherogenic Dyslipidemia; Insulin Resistance

Summary: the aims of the study are: 1. to investigate if carriers of apolipoprotein (apo) ciii loss-of-function (lof) mutations produce less apo-ciii that results in reduction of large very low-density lipoprotein (vldl) particle secretion as compared to non-carriers of these variants and compare the results with carriers of apo-ciii gain-of-function (gof) to elucidate the role of apo-ciii in hepatic lipid metabolism. 2. to study if carriers of the tm6sf2 e167k and pnlpla3 i148m mutations produce less large vldl particles to transport fat out of the liver as compared to non-carriers. 3. to test whether the specific mutations in the apo-ciii, tm6sf2 and pnlpla3 genes are reflected in changes of liver de novo lipogenesis (dnl), liver fat, homeostatic model assessment for insulin resistance (homa-ir), plasma lipid and apolipoprotein kinetics and fasting concentrations in carriers of the tm6sf2 e167k and pnlpla3 i148m mutations as compared to non-carriers. 4. to study the effects of apoe, angiopoietin (angptl3 and angptl8) or endothelial lipase (lipg) genotypes on liver fat metabolism, lipid and apolipoprotein metabolism and lipid phenotypes.


Eligibility criteria:
inclusion criteria: * persons who have provided written consent * apo-ciii loss-of-function mutation (heterozygous) or apo-ciii gain-of-function mutations (heterozygous) or tm6sf2 e167k mutation (homozygous) or pnlpla3 i148m or apoe or lipg or angptl3 or angptl8 lof and gof variants. control group without any of known risk variants in these genes. * hemoglobin a1c \< 6.5% * body mass index between 18.5 and 40 kg/m² * estimated glomerular filtration rate \> 60 ml/min/1.73 m² at inclusion exclusion criteria: * patients with type 1 and 2 diabetes, bmi \> 40 kg/m2, * apoe2/2 phenotype, thyrotropin concentration outside normal range, * lipid-lowering drugs * blood pressure \>160 mmhg systolic and/or \> 105 diastolic mmhg * liver failure or abnormal liver function tests \>3 x upper limit of normal * intestinal disease * pregnancy, breastfeeding * patients with volume depletion

Keywords: non-alcoholic fatty liver apoproteins genetic variants
the integrated population (i-pop) health trial

Conditions: Diabetes; Hypertension; Chronic Kidney Diseases; Obesity; Chronic Disease

Summary: the primary aim of this study is to determine whether community health worker (chw) navigation improves outcomes of chronic disease and chronic disease risk factors in a low-income, primarily ethnic minority population when combined with an evidence-based population health model as compared to usual care after 10 months.

the i-pop+chw participants will be paired with a chw at baseline to assist with navigation for 10-months between health and wellness services in the selected zip codes: 75210, 75215, 75216, 75217, 75223, or 75227. participants will receive a multi-level intervention utilizing the current i-pop health model that includes: 1) access to health services (including oral health), 2) access to clinical prevention services, 3) access to education and facilities to increase physical activity and improved nutrition choices, and 4) scheduled visits with chws for education and navigation. individuals will complete study measures at baseline, 6-months, and 10-months. the control group participants will receive access to the same i-pop health resources without chw navigation until the end of 10-months (delayed chw navigation). the current usual care model is outlined below (section 2.3) participants will complete study measures at baseline, 6-months, and 10-months timepoints. upon completion of 10-months measures, these individuals will be assigned a chw and receive delayed navigation.

Eligibility criteria:
inclusion criteria: * age 18 years or older * ability to alter diet and/or physical activity * willing to participate in a 10-month study * resident of selected zip codes: 75210, 75215, 75216, 75217, 75223, or 75227 * not having utilized bsw hwc membership services within the past 12 months * not planning to move outside of the selected zip code area within the next 6 months exclusion criteria: * below the age of 18 years * unable or unwilling to alter diet and/or physical activity * not willing to participate in a 10-month study * not resident of local selected zip codes: 75210, 75215, 75216, 75217, 75223, or 75227 * currently using or have used bsw hwc membership services within the past 12 months * planning to move outside of the selected zip code area within the next 6 months

Keywords: community health worker allostatic load ethnic minority health services delivery
a first-in-human study to learn about the safety of bay 3547926 and how well it works in participants with advanced liver cancer

Conditions: Hepatocellular Carcinoma

Summary: in this study, researchers want to learn about the safety of a new drug, bay 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (hcc), which has a special protein called glypican 3 (gpc3). researchers want to find the best dose of bay 3547926 for people with advanced hcc and look at the way the body absorbs and distributes the drug. the study drug, bay 3547926, delivers a radioactive agent to cancer cells. the radioactive agent emits radiations which can damage the cancer cells and cause them to die. these radiations travel a small distance, so are expected to cause little damage to surrounding healthy tissues. this is the first study of bay 3547926 in humans. participants will take part in one of the 3 different parts of the study. in part 1, participants will receive different doses of bay 3547926 alone to find the dose that is deemed safe and works best for the participants. when this dose has been found, a larger number of participants will receive bay 3547926 alone in part 2 or with other treatments in part 3 of the study. during the study, the doctors and their study team will do health check-ups, take pictures (scans) of the body, collect blood and urine samples, and ask participants questions about how they are feeling and what health problems they are having.


Eligibility criteria:
inclusion criteria: * locally advanced or metastatic and/or unresectable hcc (hepatocellular carcinoma) with histological or cytological confirmation, or non-invasive diagnosis as per american association for the study of liver diseases (aasld) criteria in participants with a confirmed diagnosis of cirrhosis. * demonstrated positive centrally confirmed gpc3 expression by immunohistochemistry (ihc) on tumor sample. * disease not amenable to, or progressive disease after, curative surgery and/or locoregional therapies of established efficacy such as resection, local ablation, chemoembolization. * eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1. * at least one measurable lesion by computed tomography (ct) scan or magnetic resonance imaging (mri) according to response evaluation criteria in solid tumours (recist) 1.1. as assessed by local site investigator within 28 days prior to the start of the study treatment. * adequate bone marrow and organ function exclusion criteria: * fibrolamellar hcc, sarcomatoid hcc, and mixed hepatocellular/cholangiocarcinoma subtypes. * participants with a history or clinical evidence of cns metastases, unless they meet specific criteria * history of encephalopathy ≥ grade 2 within the past 12 months * clinically significant ascites

Keywords: hepatocellular carcinoma (hcc) locally advanced hcc metastatic hcc unresectable hcc
rapp-children, rhinitis & asthma in patient perspective: development and validation of a questionnaire for quality of life evaluation in children with asthma and allergic rhinitis

Conditions: Asthma; Allergic Rhinitis

Summary: this observational study aims at developing and validating a simple questionnaire to be routinely applied in the clinical practice, for the evaluation of the quality of life in children with concomitant asthma and allergic rhinitis. the study consists of two phases: phase 1: development of the rapp-children questionnaire starting from the validated rhinasthma-children questionnaire. phase 2: administration and validation of the rapp-children questionnaire. 150 children with concomitant asthma and allergic rhinitis will be followed-up for one month. both at baseline and after one month, the rapp children and several other standardized questionnaires will be administered.


Eligibility criteria:
inclusion criteria: * age between 6 and 11 years * concomitant asthma and allergic rhinitis * males and females exclusion criteria: * immunological and metabolic systemic disease * major malformations of the upper airways * active smoker
intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease's lymphadenitis

Conditions: Cat-Scratch Disease

Summary: to compare effect of intra-nodal injection of gentamicin versus placebo on the outcome at 28 days of suppurated cat scratch disease's (csd) lymphadenitis treated by oral azithromycin.

double blind controlled study versus placebo. patients with suppurated csd's lymphadenitis will receive immediately after the pus aspiration (performed for a diagnostic purpose) an intra-nodal injection of gentamicin or of placebo (nacl 0,9%) and be treated with oral azithromycin for 5 days.

Eligibility criteria:
inclusion criteria: * informed consent * suppurated csd's adenitis: * suppurated form of adenitis confirmed by echography * serology positive for immunoglobulin g and/or immunoglobulin m against b. henselae exclusion criteria: * suppurated adenitis non related to csd * non-suppurated csd's adenitis * suppurated csd's adenitis already fistulized * suspected visceral b. henselae infection (neurologic or ophthalmic symptoms, hepato-splenic or valvular involvement confirmed by echography) * immunodepression (except diabetes) * pregnancy * contraindication to pus aspiration from lymphadenitis (history of bleeding or patient taking curative anticoagulation therapy or platelet count \< 50.000/mm3) * contraindication to azithromycin (history of qt interval prolongation, history of liver toxicity of hypersensitivity to macrolides or treatment with ergotamine, dihydroergotamine, bepridil, cisapride, pimozide, mizolastine or colchicine) or to aminoglycosides (myasthenia, history of hypersensitivity to aminoglycosides).

Keywords: cat scratch disease's lymphadenitis infectious diseases
the effect of early physiotherapy on biochemical parameters in major burn patients: a burn center's experience

Conditions: Burns; Physiotherapy; Exercises

Summary: background: this study planned to investigate the effect of early physiotherapy on biochemical parameters in major burn patients. methods: ten women (50%) and 10 men (50%) aged 21-47 years old were included in our study. participants were divided into two groups: one group was the treatment group and the other was the control group. in the treatment group, patients were admitted to the physiotherapy programme from the first day they have been hospitalised, in addition to their routine treatment (medical, surgery, etc.), for 4 days per week. it consisted of parameters such as early mobilisation and ambulatory training, chest physiotherapy, and both active and passive normal joint movement exercises. the days of treatment were determined as tuesday, wednesday, thursday and friday. patients could not be treated on a monday because that was surgery day. the control group consisted of patients who could not receive physiotherapy due to various reasons. all patients included in the study were evaluated weekly for 6 weeks after admission to the hospital. parameters such as demographic information, characteristics of burn injury, c-reactive protein, fibronectin, transferrin and prealbumin were evaluated.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * major burn injury (according to aba) * conscious patients exclusion criteria: * inhalation injury * various chronic disorders * organ dysfunctions

Keywords: fibronectin prealbumin physiotherapy major burns biochemical parameters
clinical performance of dentals implants with hydrophilic or hydrophobic surfaces

Conditions: Tooth Loss

Summary: the aim of the study is to compare longitudinally the clinical performance of dental implants with different surfaces placed in single tooth gaps at the posterior maxilla and mandible of adults. it is a randomized clinical trial, in which participants will be randomly allocated to two groups: test group (implants with hydrophilic surface) and control group (implants with hydrophobic surface). the null hypothesis is that the implant stability quotient of hydrophilic and hydrophobic dental implants show a similar progression after placement in posterior tooth gaps.


Eligibility criteria:
inclusion criteria: * present single or multiple intercalated untreated tooth gaps in the posterior region of the mandible or maxilla; * agree to participate in the study by signing the informed consent form. exclusion criteria: * unavailability for participation or signs that they could not comply with the schedule of follow-up visits; * presence of general and/or local contraindications that could prevent the surgical procedure for implant placement; * presence of conditions that may interfere with the prognosis, such as current treatment with bisphosphonates or report of use for less than 2 years, presence of rheumatic diseases, among others; * absence of the minimum bone quantity of 8 mm in length and 3.75 mm in diameter for installation of an implant in the tooth gap; * absence of a mesio-distal space of at least 4.6 mm in the single tooth gap required to place the surgical guide; * do not present a mouth opening of at least 12mm required for the proper of the guided surgical kit together with the surgical guide; * do not present a band of keratinized tissue favorable for maintaining peri-implant health. * present motor difficulties that compromise adequate oral hygiene.

Keywords: single tooth gap missing tooth
biobank for inflammatory chronic diseases and osteoporosis

Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Spondyloarthritis; Osteoporosis

Summary: the aim of this study is to constitute a biobank for patients followed in the rheumatology center of toulouse university hospital for a chronic inflammatory rheumatism including rheumatoid arthritis (ra), spondyloarthritis(spa), and psoriatic arthritis (psa) or a chronic bone disease including osteoporosis in order to identify biomarkers associated with therapeutic response.

biologic ant targeted synthetic disease modifying anti-rheumatic drugs (bdmards and tsdmards) have greatly improved the prognosis of chronic inflammatory diseases. to date, many bdmards and tsdmards targeting different immunologic mechanisms are available to treat ra, spa or psa. however, the choice of the treatment and its mechanism of action is based on physician decision and experience. indeed, predictive clinical and biological factors associated with therapeutic response that could help the physician to make his/her choice are lacking. the aim of biotoul is to collect and store biologic samples in patients with ra, spa or psa who begin a new bdmard or tsdmard. this biobank will permit to study several biomarkers and assess the association between such markers and response to therapy. furthermore, osteoporosis is a chronic disease leading to fractures and disability. several ant-osteoporotic drugs are now available and biomarker(s) that would help the physician to choose the best therapeutic sequence are lacking. biotoul will also include patients with osteoporosis to identify biomarkers associated with severity and response to anti-osteoporotic treatments.

Eligibility criteria:
inclusion criteria: * chronic inflammatory rheumatism including ra, spa or psa or patients with primary or secondary osteoporosis * with national health assurance * able to consent to the study exclusion criteria: * pregnancy or breastfeeding * not able to give a consent * severe anemia (hb\<10g/l)
clinical study on the distribution of digestive tract microbiota before and after ileocecal resection in crohn's disease

Conditions: Crohn Disease; Microtia; Ileocecal; Lesion

Summary: in this study, the microbiota sequencing was used to investigate the changes of microbiota in the terminal ileum and the middle part of ascending colon, the mesenteric adipose tissue of ileum and ascending mesocolon, and oral cavity of patients with crohn's disease before and after ileocecal resection, so as to further explore the role of ileocecal region in inducing remission of disease.


Eligibility criteria:
inclusion criteria: clinical diagnosis of crohn's disease exclusion criteria: serious oral diseases (e.g. dental caries, periodontal disease) other acute or chronic gastrointestinal diseases probiotics or prebiotic consumption and antibiotic use within 1 month
effect of mild therapeutic hypothermia on the doses of vasopressors and inotropes in cardiogenic shock complicating acute myocardial infarction

Conditions: Mild Therapeutic Hypothermia; Cardiogenic Shock; Acute Myocardial Infarction; Vasopressors; Inotropes

Summary: the study aimed to assess the effects of mild therapeutic hypothermia (mth) on vasopressors and inotropes in patients with cardiogenic shock (cs) due to acute myocardial infarction (ami).

cardiogenic shock (cs) is a condition characterized by a severe lack of blood flow to vital organs caused by primary malfunction of the heart, as described by the european society of cardiology (esc) and the american heart association (aha). acute myocardial infarction (ami) is a prevalent etiology of cs, constituting a minimum of 30% of the instances. 50% of cs cases manifest upon hospital admission, whereas the remaining 50% occur after hospital admission.

Eligibility criteria:
inclusion criteria: * age from 50 to 70 years. * both sexes. * cardiogenic shock post ami defined by systolic blood pressure \ 30 minutes or motropes required to maintain a systolic blood pressure \>90 mm hg in the absence of hypovolemia with signs of pulmonary congestion and signs of impaired organ perfusion defined by at least 1 of the following: altered mental status; cold, clammy skin; urine output \ 2 mmol/l. 2. intubated and sedated exclusion criteria: 1. self-ventilated 2. indication for targeted temperature management by current guidelines "out of hospital cardiac arrest with return of spontaneous circulation (rosc)"